16 The pituitary and the adrenal cortex Flashcards
16.01 HYPOTHALAMIC HORMONES
Somatostatin analogues: octreotide, lanreotide, pasireotide - actions
octapeptide analogues of natural somatostatin
they inhibit various endocrine, neuroendocrine, exocrine and paracrine functions
16.01 HYPOTHALAMIC HORMONES
Somatostatin analogues: octreotide, lanreotide, pasireotide - MOA
inhibit pathologically increased secretion of growth hormone (GH) and of peptides and serotonin produced within the gastro-entero-pancreatic endocrine system
octreotide also constricts splanchnic blood vessels
16.01 HYPOTHALAMIC HORMONES
Somatostatin analogues: octreotide, lanreotide, pasireotide - abs/distrib/elim
given SC
octreotide: peak action is at 2h, and the suppressant effect lasts for up to 8h
16.01 HYPOTHALAMIC HORMONES
Somatostatin analogues: octreotide, lanreotide, pasireotide - clinical use
octreotide: carcinoid, hormone-secreting tumours, acromegaly, bleeding oesophageal varices
lanreotide: thyroid tumours
pasireotide: Cushing’s syndrome when surgery is inappropriate or has been ineffective
16.01 HYPOTHALAMIC HORMONES
Somatostatin analogues: octreotide, lanreotide, pasireotide - adverse effects
pain at injection site and GI disturbances
gallstones, post-prandial hyperglycaemia
cases of hepatitis and pancreatitis have also been reported
16.02 HYPOTHALAMIC HORMONES
GnRH analogues: buserelin, leuprorelin, gonadorelin - actions
stimulate the synthesis of follicle-stimulating hormone (FSH) and luteinising hormone (LH) and their release
16.02 HYPOTHALAMIC HORMONES
GnRH analogues: buserelin, leuprorelin, gonadorelin - MOA
analogues of natural gonadotrophin-releasing hormone (gonadorelin, LHRH or GnRH)
after an initial stimulation of gonadotrophin release, it down-regulates the hypothalamic-pituitary-gonadal (HPG, also called HPO) axis such that a decrease in ovarian steroid secretion into the postmenopausal range occurs
16.02 HYPOTHALAMIC HORMONES
GnRH analogues: buserelin, leuprorelin, gonadorelin - abs/distrib/elim
given by SC injection
gonadorelin is rapidly hydrolysed in plasma and excreted in urine with a half-life of ~4 min
buserelin half-life after injection is ~80 min
16.02 HYPOTHALAMIC HORMONES
GnRH analogues: buserelin, leuprorelin, gonadorelin - clinical use
evaluation of anterior pituitary hormones
endometriosis, infertility treatment, hormone-dependent tumours
16.02 HYPOTHALAMIC HORMONES
GnRH analogues: buserelin, leuprorelin, gonadorelin - adverse effects
weight changes, mood changes, sleep disturbances, GI disturbances, dizziness
risk of skeletal fractures increases with duration of therapy (decrease in bone mass may occur)
16.03 ANTERIOR PITUITARY HORMONES
Prolactin inhibitors: bromocriptine, cabergoline, quinagolide - actions
inhibit prolactin secretion
16.03 ANTERIOR PITUITARY HORMONES
Prolactin inhibitors: bromocriptine, cabergoline, quinagolide - MOA
inhibit prolactin secretion without affecting normal levels of other pituitary hormones
bromocriptine can also reduce elevated levels of growth hormone (GH) in patients with acromegaly
these effects are due to stimulation of dopamine receptors
16.03 ANTERIOR PITUITARY HORMONES
Prolactin inhibitors: bromocriptine, cabergoline, quinagolide - abs/distrib/elim
given orally
metabolised by liver
bromocriptine peak concentrations occur after 2h
16.03 ANTERIOR PITUITARY HORMONES
Prolactin inhibitors: bromocriptine, cabergoline, quinagolide - clinical use
prolactinomas
acromegaly
infertility
hyperprolactinaemia
polycystic ovarian syndrome
16.03 ANTERIOR PITUITARY HORMONES
Prolactin inhibitors: bromocriptine, cabergoline, quinagolide - adverse effects
nausea, vomiting, dizziness, constipation, postural hypotension